Corporate Update: Zhejiang Huahai Pharmaceutical (600521.SS)
Zhejiang Huahai Pharmaceutical, listed on the Shanghai Stock Exchange, reported that its shares traded flat during the 24‑hour period ending at 02:29 PM Central Europe on Wednesday, 21 April 2026. The most recent trading price is approximately CNY 16.63 per share on major exchanges.
- Outstanding Shares: 1.5 billion
- Market Capitalisation: CNY 3.5 billion
- 24‑Hour Trading Volume: CNY 419.9 million
Since the close of the previous month, the stock has risen by 0.48 %. The 200‑day simple moving average sits at CNY 16.11. The share’s 52‑week range extends from a low of CNY 13.73 (29 June 2026) to a high of CNY 19.43 (28 October 2025).
Earnings Preview for the Third Quarter
In a recent filing, Zhejiang Huahai Pharmaceutical released a preview of its third‑quarter earnings, projecting a notable increase in net profit for the first nine months of the fiscal year. The company attributes this growth to:
- Expansion of specialty raw‑material and biologics manufacturing lines.
- Broader global sales channels that are delivering higher volumes of new products.
- Improved operational efficiency in both domestic and U.S. formulation businesses.
Market analysts note that these developments align with a sector‑wide shift toward high‑value manufacturing and international collaboration. Firms that have successfully moved from research investment toward commercial delivery are experiencing stronger profitability, and Zhejiang Huahai Pharmaceutical’s trajectory appears to reflect that trend.
Recent Performance of Peer Stocks
| Stock | 24‑Hour Movement | Current Price | Market Cap | P/E Ratio | Notes |
|---|---|---|---|---|---|
| Wuxi Lead Intelligent Equi‑h (0470.HK) | +1.64 % | HKD 19.06 | HKD 35.3 bn | 28.68 | Stronger performance than the market. |
| Boc China (601696.SS) | 0 % | CNY 10.75 | CNY 30.1 bn | 26.79 | Stable trading. |
| Gem (002340.SZ) | 0 % | CNY 5.91 | CNY 30 bn | 16.45 | Preparing to discuss output cuts with Indonesian peers due to weak nickel/cobalt prices. |
| Olympic Circuit (603920.SS) | 0 % | CNY 40.9 | CNY 30 bn | 78.02 | Revenue rose in Q3, but net profit fell due to raw‑material costs and FX losses. |
| Chongqing Zhifei Biologica (300122.SZ) | 0 % | CNY 12.74 | CNY 29.9 bn | – | Stable trading. |
Company Overview
Zhejiang Huahai Pharmaceutical Co., Ltd. is headquartered in Linhai, China, and specializes in the manufacturing and retailing of pharmaceutical products and medical raw materials. The company serves a global customer base, exporting to numerous countries worldwide. For additional information, visit the company’s website at www.huahaipharm.com .
The firm went public on February 17, 2003, and its shares are currently traded on the Shanghai Stock Exchange.